Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
nifuroxazide
Bosnalijek d.d.
A07AX03
nifuroxazide
100mg
capsules
(30/3x10/) in blister
Prescription
Registered
2022-11-21
1. NAME OF THE MEDICINAL PRODUCT ENTEROFURYL ® 100 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ENTEROFURYL ® 100 mg capsule contains: Nifuroxazide 100.00 mg See section 6.1. for excipients. 3. PHARMACEUTICAL FORM Capsule, hard. Oblong, hard gelatin capsules made of body and cap. Capsules are yellow. Capsule size is 2. Capsule content is yellow granulate or mildly compressed granulate that disintegrates upon slight pressure. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Acute bacterial diarrhea without of aggravation of the general condition, fever, intoxication signs. 4.2.DOSAGE AND METHOD OF ADMINISTRATION _METHOD OF ADMINISTRATION _ The medicine is intended for oral administration. _DOSAGE _ Children from 6 to 18 years of age: 200 mg of nifuroxazide (2 capsules) 3 - 4 times a day with dosing interval of 6 - 8 h. Totally 600 - 800 mg of nifuroxazide a day. Adults: 200 mg of nifuroxazide (2 capsules) 4 times a day with dosing interval of 6 h. Totally 800 mg of nifuroxazide a day. The duration of treatment is 5 – 7 days but not more than 7 days. If no improvement occurs within the first 3 days of treatment, the patient should consult a doctor. 4.3. CONTRAINDICATIONS • Hypersensitivity to nifuroxazide, nitrofuran derivatives and other ingredients of the product; • Age under 6 years (for this pharmaceutical form); • Intolerance to fructose, glucose-galactose malabsorption or saccharose-isomaltase insufficiency. 4.4.SPECIAL WARNINGS AND PRECAUTIONS FOR USE In diarrhea treatment rehydration therapy should be conducted simultaneously with nifuroxazide therapy. In case of bacterial diarrhea with the signs of systemic lesion (aggravation of the general condition, fever, intoxication or infection signs) a medical consultation is required in order for a decision to be made on whether to use antibacterial systemic agents. In case of expression of the symptoms of hypersensitivity (dyspnea, rush, itch) the treatment with nifuroxazide should be discontinued. Alcohol consumption is forbidden du Read the complete document